Effects of a new calcium channel blocker, MPC-1304, on blood pressure, serum lipoproteins and serum carbohydrate metabolism in patients with essential hypertension. 1995

J Sasaki, and G Kajiyama, and R Kusukawa, and M Shichiri, and T Sunaga, and H Mashiba, and N Tanaka, and K Nonaka, and K Arakawa
Second Department of Internal Medicine, Fukuoka University School of Medicine, Japan.

The effects of MPC-1304, a new calcium channel blocker, on blood pressure, serum lipoproteins, and carbohydrate metabolism were compared with those of atenolol in a group of patients with mild to moderate essential hypertension. Systolic and diastolic pressures were significantly decreased by both MPC-1304 and atenolol administration. Serum levels of apolipoproteins A-I and A-II were significantly increased after 8-12 weeks of MPC-1304 treatment, but were unchanged during a similar period of atenolol treatment. Neither drug induced any significant change in other lipoprotein parameters, fasting blood sugar, immunoreactive insulin, C-peptide or HbA1c. No serious side-effects or abnormal laboratory values were observed during the course of administration of either drug. These findings indicated that MPC-1304 is as efficacious as an antihypertensive drug and is without adverse effect on lipoprotein or carbohydrate metabolism.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D008074 Lipoproteins Lipid-protein complexes involved in the transportation and metabolism of lipids in the body. They are spherical particles consisting of a hydrophobic core of TRIGLYCERIDES and CHOLESTEROL ESTERS surrounded by a layer of hydrophilic free CHOLESTEROL; PHOSPHOLIPIDS; and APOLIPOPROTEINS. Lipoproteins are classified by their varying buoyant density and sizes. Circulating Lipoproteins,Lipoprotein,Lipoproteins, Circulating
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001786 Blood Glucose Glucose in blood. Blood Sugar,Glucose, Blood,Sugar, Blood
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D002096 C-Peptide The middle segment of proinsulin that is between the N-terminal B-chain and the C-terminal A-chain. It is a pancreatic peptide of about 31 residues, depending on the species. Upon proteolytic cleavage of proinsulin, equimolar INSULIN and C-peptide are released. C-peptide immunoassay has been used to assess pancreatic beta cell function in diabetic patients with circulating insulin antibodies or exogenous insulin. Half-life of C-peptide is 30 min, almost 8 times that of insulin. Proinsulin C-Peptide,C-Peptide, Proinsulin,Connecting Peptide,C Peptide,C Peptide, Proinsulin,Proinsulin C Peptide
D002121 Calcium Channel Blockers A class of drugs that act by selective inhibition of calcium influx through cellular membranes. Calcium Antagonists, Exogenous,Calcium Blockaders, Exogenous,Calcium Channel Antagonist,Calcium Channel Blocker,Calcium Channel Blocking Drug,Calcium Inhibitors, Exogenous,Channel Blockers, Calcium,Exogenous Calcium Blockader,Exogenous Calcium Inhibitor,Calcium Channel Antagonists,Calcium Channel Blocking Drugs,Exogenous Calcium Antagonists,Exogenous Calcium Blockaders,Exogenous Calcium Inhibitors,Antagonist, Calcium Channel,Antagonists, Calcium Channel,Antagonists, Exogenous Calcium,Blockader, Exogenous Calcium,Blocker, Calcium Channel,Blockers, Calcium Channel,Calcium Blockader, Exogenous,Calcium Inhibitor, Exogenous,Channel Antagonist, Calcium,Channel Blocker, Calcium,Inhibitor, Exogenous Calcium
D004095 Dihydropyridines Pyridine moieties which are partially saturated by the addition of two hydrogen atoms in any position.
D006339 Heart Rate The number of times the HEART VENTRICLES contract per unit of time, usually per minute. Cardiac Rate,Chronotropism, Cardiac,Heart Rate Control,Heartbeat,Pulse Rate,Cardiac Chronotropy,Cardiac Chronotropism,Cardiac Rates,Chronotropy, Cardiac,Control, Heart Rate,Heart Rates,Heartbeats,Pulse Rates,Rate Control, Heart,Rate, Cardiac,Rate, Heart,Rate, Pulse

Related Publications

J Sasaki, and G Kajiyama, and R Kusukawa, and M Shichiri, and T Sunaga, and H Mashiba, and N Tanaka, and K Nonaka, and K Arakawa
August 1992, International journal of clinical pharmacology, therapy, and toxicology,
J Sasaki, and G Kajiyama, and R Kusukawa, and M Shichiri, and T Sunaga, and H Mashiba, and N Tanaka, and K Nonaka, and K Arakawa
December 1996, American journal of therapeutics,
J Sasaki, and G Kajiyama, and R Kusukawa, and M Shichiri, and T Sunaga, and H Mashiba, and N Tanaka, and K Nonaka, and K Arakawa
January 1990, Clinical therapeutics,
J Sasaki, and G Kajiyama, and R Kusukawa, and M Shichiri, and T Sunaga, and H Mashiba, and N Tanaka, and K Nonaka, and K Arakawa
December 1987, Journal of clinical hypertension,
J Sasaki, and G Kajiyama, and R Kusukawa, and M Shichiri, and T Sunaga, and H Mashiba, and N Tanaka, and K Nonaka, and K Arakawa
January 1986, Journal of cardiovascular pharmacology,
J Sasaki, and G Kajiyama, and R Kusukawa, and M Shichiri, and T Sunaga, and H Mashiba, and N Tanaka, and K Nonaka, and K Arakawa
April 1986, Research communications in chemical pathology and pharmacology,
J Sasaki, and G Kajiyama, and R Kusukawa, and M Shichiri, and T Sunaga, and H Mashiba, and N Tanaka, and K Nonaka, and K Arakawa
July 2005, Blood pressure. Supplement,
J Sasaki, and G Kajiyama, and R Kusukawa, and M Shichiri, and T Sunaga, and H Mashiba, and N Tanaka, and K Nonaka, and K Arakawa
June 2007, Journal of cardiovascular pharmacology,
J Sasaki, and G Kajiyama, and R Kusukawa, and M Shichiri, and T Sunaga, and H Mashiba, and N Tanaka, and K Nonaka, and K Arakawa
February 2013, International angiology : a journal of the International Union of Angiology,
J Sasaki, and G Kajiyama, and R Kusukawa, and M Shichiri, and T Sunaga, and H Mashiba, and N Tanaka, and K Nonaka, and K Arakawa
January 2009, Clinical drug investigation,
Copied contents to your clipboard!